Next Article in Journal
Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review
Next Article in Special Issue
Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci
Previous Article in Journal
Suppressive Antibiotic Treatment in Prosthetic Joint Infections: A Perspective
Previous Article in Special Issue
Resistance and Adaptation of Bacteria to Non-Antibiotic Antibacterial Agents: Physical Stressors, Nanoparticles, and Bacteriophages
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019

1
Family & Community Medicine, College of Medicine, Jouf University, 74311 Sakaka, Aljouf, Saudi Arabia
2
Ex-faculty, Department of microbiology, College of Medicine, Jouf University, 74311 Sakaka, Aljouf, Saudi Arabia
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(6), 744; https://doi.org/10.3390/antibiotics10060744
Submission received: 14 May 2021 / Revised: 15 June 2021 / Accepted: 16 June 2021 / Published: 19 June 2021

Abstract

Antimicrobial-resistance in Enterobacterales is a serious concern in Saudi Arabia. The present study retrospectively analyzed the antibiograms of Enterobacterales identified from 1 January 2019 to 31 December 2019 from a referral hospital in the Aljouf region of Saudi Arabia. The revised document of the Centers for Disease Control (CDC) CR-2015 and Magiorakos et al.’s document were used to define carbapenem resistance and classify resistant bacteria, respectively. The association of carbapenem resistance, MDR, and ESBL with various sociodemographic characteristics was assessed by the chi-square test and odds ratios. In total, 617 Enterobacterales were identified. The predominant (n = 533 (86.4%)) isolates consisted of 232 (37.6%), 200 (32.4%), and 101 (16.4%) Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, respectively. In general, 432 (81.0%) and 128 (24.0%) isolates were of MDR and ESBL, respectively. The MDR strains were recovered in higher frequency from intensive care units (OR = 3.24 (1.78–5.91); p < 0.01). E. coli and K. pneumoniae resistance rates to imipenem (2.55 (1.21–5.37); p < 0.01) and meropenem (2.18 (1.01–4.67); p < 0.04), respectively, were significantly higher in winter. The data emphasize that MDR isolates among Enterobacterales are highly prevalent. The studied Enterobacterales exhibited seasonal variation in antimicrobial resistance rates towards carbapenems and ESBL activity.
Keywords: Enterobacterales; E. coli; K. pneumoniae; P. mirabilis; antimicrobials; multidrug resistance; carbapenem; ESBL Enterobacterales; E. coli; K. pneumoniae; P. mirabilis; antimicrobials; multidrug resistance; carbapenem; ESBL

Share and Cite

MDPI and ACS Style

Bandy, A.; Tantry, B. ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019. Antibiotics 2021, 10, 744. https://doi.org/10.3390/antibiotics10060744

AMA Style

Bandy A, Tantry B. ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019. Antibiotics. 2021; 10(6):744. https://doi.org/10.3390/antibiotics10060744

Chicago/Turabian Style

Bandy, Altaf, and Bilal Tantry. 2021. "ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019" Antibiotics 10, no. 6: 744. https://doi.org/10.3390/antibiotics10060744

APA Style

Bandy, A., & Tantry, B. (2021). ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019. Antibiotics, 10(6), 744. https://doi.org/10.3390/antibiotics10060744

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop